The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. (17th December 2014)

• Record Type: Journal Article
• Authors: Weißbach, Susann; Langer, Christian; Puppe, Bernhard; Nedeva, Theodora; Bach, Elisa; Kull, Miriam; Bargou, Ralf; Einsele, Hermann; Rosenwald, Andreas; Knop, Stefan; Leich, Ellen
• Is Part Of: British journal of haematology. Volume 169:Number 1(2015:Apr.)
• Page Start: 57
• Page End: 70
• Publication Date: 2014-12-17
• Subjects: multiple myeloma -- DIS3 -- bortezomib -- ultra‐deep amplicon sequencing -- hot spot mutations; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.13256
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Multiple myeloma (MM) is a plasma cell neoplasm that presents with a major biological and clinical heterogeneity. We here investigated the spectrum of clonal and subclonal mutations of DIS3, an active part of the exosome complex, that may play a role in the development or progression of MM. The whole coding sequence of DIS3 was subjected to deep sequencing in 81 uniformly‐treated MM patients and 12 MM cell lines and the overall occurrence of DIS3 mutations as well as the presence of DIS3 mutations in minor and major subclones were correlated with cytogenetic alterations and clinical parameters. Our study identified DIS3 mutations in 9/81 patients that were associated with 13q14 deletions and IGH translocations on the cytogenetic level. Specifically, we detected seven novel somatic DIS3 single nucleotide variants (SNVs) and defined three hot spot mutations within the RNB domain. Lastly, we found a trend towards a shorter median overall survival for patients with DIS3 mutations, and patients carrying DIS3 mutations in minor subclones of their tumours showed a significantly worse response to therapy compared to patients with DIS3 mutations in the major subclone.